Sabra Health Care REIT reports today with a clear tension at its core: short sellers have been quietly exiting even as the stock has slid sharply in the past week, creating a divergence that makes the positioning picture more nuanced than the price action alone suggests.
Short interest has fallen roughly 6% over the past week and more than 7% over the past month, dropping to just under 10% of the free float — a meaningful level, but one that is actively shrinking. The borrow market is loose, with availability running at 367%, well above the 52-week floor of 249%, meaning there is no squeeze pressure and no friction for new shorts to enter. Cost to borrow remains negligible at 0.44%. The lending setup does not support a short-squeeze narrative; it simply shows that existing bears have been covering. That retreat in short interest comes even as the stock has given back nearly 8% over the past week to close at $20.61, down 2.6% on Monday alone — a disconnect that suggests the selling pressure is coming from elsewhere, not from short-side conviction building.
Options positioning has tilted modestly more defensive into the print. The put/call ratio ticked up to 0.39, above its 20-day average of 0.31 — not an extreme reading, sitting less than one standard deviation above the mean, but the direction is clear. Healthcare REIT peers sold off broadly on the week: fell 7%, lost 7%, dropped roughly 2%, and gave back 3%. 's 8% decline was steeper than most, suggesting some stock-specific pressure compounding the sector-wide move rather than pure macro drag.
The analyst debate heading into the print is genuinely split. On the bull side, three firms — Baird, Truist Securities, and Citizens — all raised their price targets on July 22, the most recent analyst activity, with Truist upgrading to Buy from Hold earlier in the month and setting a $24 target. The bull case rests on the re-tenancy of all Avamere properties at a 30% premium and the repayment of a $300 million mortgage loan that frees up balance sheet capacity. Bears counter that the transition to Cascadia Healthcare carries execution risk given Cascadia's checkered history with prior takeovers, and that cash NOI growth has been modest relative to the optionism baked into bullish targets. UBS nudged its target down to $21 on July 8 and holds a Neutral rating, while Barclays initiated at Equal-Weight with a matching $21 target — together they frame a floor at or near current prices. The mean analyst target sits at $22.71, implying about 10% upside from Monday's close, but the stock's sharp weekly slide has eaten through much of that cushion.
JP Morgan Asset Management notably added over 5.3 million shares in the most recent reporting period, making it a meaningful new presence in the top holder list alongside long-standing anchor positions from BlackRock at 15.5% and Principal Global at 9.9%. That institutional accumulation may provide some support, though it predates the recent pullback. Today's print will test whether Sabra's operational momentum — particularly the Avamere transition economics and SHOP portfolio rent trajectory — is strong enough to justify the valuation premium that even cautious analysts have been reluctant to abandon.
See the live data behind this article on ORTEX.
Open SBRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
